Neuland Laboratories vs Suven Pharmaceuticals: Share Price, Comparison and Key Differences

Neuland Laboratories vs Suven Pharmaceuticals is a comparison API and CDMO investors look up when evaluating two listed Indian pharmaceutical companies specialised in active pharmaceutical ingredients for complex molecules. Neuland Laboratories, a Hyderabad-based company, manufactures APIs for global regulated markets including CNS, peptide, oncology and other complex molecule APIs. Suven Pharmaceuticals, also Hyderabad-based and demerged from Suven Life Sciences, is a CDMO focused on CNS (central nervous system) drug intermediates, neurology APIs and contract manufacturing for global innovator pharmaceutical companies. Neuland vs Suven represent two Hyderabad-based API and CDMO specialists in complex molecules.

This Neuland Laboratories vs Suven Pharmaceuticals article covers reach and market position, key products, latest declared results and stock valuation. The Neuland Laboratories vs Suven Pharmaceuticals data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Neuland Laboratories vs Suven Pharmaceuticals: Reach and Market Position

On the Neuland Laboratories side of the Neuland Laboratories vs Suven Pharmaceuticals comparison, Neuland Laboratories supplies APIs to regulated markets in the US, Europe and Japan for CNS, anti-bacterial and oncology active ingredients. Market capitalisation is Rs 29,308 Cr.

Click Here – Get Free Investment Predictions

On the Suven Pharmaceuticals side of the Neuland Laboratories vs Suven Pharmaceuticals comparison, Suven Pharmaceuticals provides CDMO services for CNS drug intermediates, APIs and formulations for global innovator pharma companies. Market capitalisation is approximately Rs 7,000 Cr.

Neuland Laboratories vs Suven Pharmaceuticals: Key Products and Business Mix

In the Neuland Laboratories vs Suven Pharmaceuticals product comparison, Neuland Laboratories offers: Neuland earns from generic APIs (peptides, CNS, oncology) and prime products for global pharma. EPS is Rs 387.98. PE is 58.88x, ROE 19.42 percent, D/E 0.16.

For Suven Pharmaceuticals in this Neuland Laboratories vs Suven Pharmaceuticals breakdown: Suven Pharmaceuticals earns from CDMO contracts for CNS intermediates and APIs. PE is approximately 45x, ROE approximately 15 percent. (Note: Suven Pharmaceuticals data is approximate – investors should verify current figures from exchange filings.)

Neuland Laboratories vs Suven Pharmaceuticals: Latest Results

The Neuland Laboratories vs Suven Pharmaceuticals results for Neuland Laboratories: Neuland Laboratories has a market cap of Rs 29,308 Cr and PE of 58.88x. ROE is 19.42 percent. Neuland is approximately 4.2 times larger than Suven Pharmaceuticals.

The Neuland Laboratories vs Suven Pharmaceuticals results for Suven Pharmaceuticals: Suven Pharmaceuticals has a market cap of approximately Rs 7,000 Cr. The company is a CDMO for CNS innovator drug programmes with a high proportion of repeat business from global innovator pharma partners.

Compare Neuland Laboratories and Suven Pharmaceuticals Fundamentals on the Univest Screener

Neuland Laboratories vs Suven Pharmaceuticals: Stock and Valuation

The Neuland Laboratories vs Suven Pharmaceuticals stock comparison uses the latest available market data from Groww. Investors tracking Neuland Laboratories vs Suven Pharmaceuticals should verify current prices on NSE or BSE before trading.

Neuland Laboratories vs Suven Pharmaceuticals at current valuations: Neuland trades at Rs 29,308 Cr market cap, PE 58.88x, ROE 19.42 percent. Suven trades at approximately Rs 7,000 Cr market cap, PE approximately 45x. Neuland is significantly larger with higher ROE and greater earnings visibility.

Neuland Laboratories vs Suven Pharmaceuticals: Quick Comparison Table

The Neuland Laboratories vs Suven Pharmaceuticals comparison table below summarises the key metrics covered in this article side by side.

Parameter	Neuland Laboratories	Suven Pharmaceuticals
Sector	Complex APIs: CNS, peptides, oncology (global regulated markets)	CDMO: CNS intermediates and APIs for innovator pharma
Market Cap	Rs 29,308 Cr	Approx Rs 7,000 Cr
P/E Ratio	58.88x	Approx 45x
ROE	19.42%	Approx 15%
Debt to Equity	0.16	Low
Key Focus	Generic APIs + prime products for regulated markets	CDMO for CNS innovator programmes
Geography	US, Europe, Japan export	Global innovator pharma partners

Conclusion

The Neuland Laboratories vs Suven Pharmaceuticals comparison above covers the key data points on reach, products, results and valuation. Neuland Laboratories vs Suven Pharmaceuticals covers two Hyderabad-based API and CDMO specialists in complex CNS molecules. Neuland has a broader API portfolio and an established global regulatory track record. Suven has a focused CNS CDMO model with innovator pharma relationships. Neuland vs Suven investors should review API approval timelines, CDMO order wins, USFDA inspection outcomes and complex molecule launch timing. Both Neuland vs Suven are niche API/CDMO companies. Consult a SEBI-registered advisor for personalised guidance.

Download the Univest iOS App or Univest Android App to track Neuland Laboratories and Suven Pharmaceuticals live price and get daily stock recommendations.

Frequently Asked Questions

What does Neuland Laboratories make?

Ans. Neuland Laboratories manufactures complex APIs (Active Pharmaceutical Ingredients) for global regulated markets – particularly CNS (antidepressants, anti-anxiety), peptide APIs, anti-infectives and oncology molecules. It sells bulk APIs to finished dosage manufacturers globally.

What is Suven Pharmaceuticals?

Ans. Suven Pharmaceuticals is a Hyderabad-based CDMO demerged from Suven Life Sciences. It provides contract manufacturing for CNS (central nervous system) drug intermediates, APIs and formulations to global innovator pharmaceutical companies.

What is a CNS drug?

Ans. A CNS (Central Nervous System) drug acts on the brain and nervous system – treating conditions like depression, anxiety, Parkinson's, Alzheimer's, schizophrenia and epilepsy. Both Neuland and Suven specialise in complex CNS molecule manufacturing.

What makes Neuland unique?

Ans. Neuland Laboratories is known for manufacturing challenging APIs through complex chemistry – particularly peptides and stereoselective syntheses – that require high technical capability and regulatory expertise.

Are Neuland and Suven in Nifty 50?

Ans. Neither is in Nifty 50. Both are tracked in smaller indices.

Which is larger, Neuland or Suven?

Ans. Neuland Laboratories at Rs 29,308 Cr is approximately 4.2 times larger than Suven Pharmaceuticals at approximately Rs 7,000 Cr.

Does Neuland pay dividends?

Ans. Yes. Neuland Laboratories pays a small dividend yield of approximately 0.15 percent.